Mihuzo

Despite a second-quarter earnings loss, Audentes Therapeutics, Inc. (NASDAQ: BOLD)’s existing catalysts are reason enough for a bullish stance, according to Mizuho.  The Analyst Mihuzo analyst Difei Yang upgraded Audentes Therapeutics from Neutral to Buy and raised the price target...